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Objectives. In view of previous experimental evidence relating 
sympathetic nervous overactivity in the heart to myocardial 
necrosis and ventricular rrhythmias, we prospectively examined 
the hypothesis that heightened cardiac sympathetic nervous ac- 
tivity is associated with an adverse outcome in patients with 
moderate to severe heart failure. 
Background. Despite recent therapeutic advances, patients with 
heart failure continue to have high mortality from progressive 
hemodynamic decompensation a d lethal ventricular arrhyth- 
mias. It is believed that initially compensatory increases in 
sympathetic nervous ystem activity may ultimately be maladap- 
tive, potentially contributing to subsequent adverse vents. 
Methods. Sixty patients with moderate to severe heart failure 
(left ventricular ejection fraction 18.9 -+ 0.9% [mean _+ SE]) were 
studied prospectively. In addition to the compilation of a bemo- 
dynamic, biochemical nd electrocardiographic profile for each 
patient, whole-body and cardiac sympathetic a tivity were deter- 
mined by isotope dilution. The relation of these variables to 
outcome was determined by Cox proportional hazards analysis. 
Results. The mean follow-up eriod of the study group was 7 --- 
1 months (range 1 to 24) with a 12-month actuarial survival of 
75%. Deaths (14 in all) were accounted for either by sudden death 
or progressive heart failure in equal numbers. The rate of release 
of norepinephrine from the heart was significantly higher in 
patients with heart failure than in healthy subjects (402 "¢- 37 vs. 
105 -+ 19 pmol/min, p < 0.01), although the values for heart 
failure ranged widely from normal to 10 times normal. By 
univariate Cox proportional hazards analysis, pulmonary capil. 
lary wedge pressure (p < 0.01), mean pulmonary artery pressure 
(p < 0.001), serum sodium levels (p < 0.01) and cardiac norepi. 
nephrine spill-over rate (p < 0.001) were identified as significant 
prognostic markers. In a multivariate analysis, cardiac norepineph- 
rine spillover ate was identified as the most powerful prognostic 
marker (p = 0.0006) of those valuated in this study, 
Conclusions. These results uggest that activation of the sym- 
pathetic nervous ystem in patients with heart failure, specifically 
the cardiac sympathetic nerves, may contribute to the poor 
prognosis associated with severe heart failure. The data therefore 
provide a rationale for the use of drugs such as beta-adrenergic 
blocking agents in the management of patients with heart failure. 
(J Am Coil Cardiol 1995;26:1257-63) 
Despite recent important therapeutic advances in the manage- 
ment of heart failure, patients with end-stage cardiac failure 
continue to be exposed to a significant risk of death, largely 
attributable to either progressive hemodynamic decompensa- 
tion or lethal ventricular arrhythmias (1,2). Characteristically, 
the sympathetic nervous ystem is stimulated in patients with 
heart failure, and this phenomenon has been ascribed apivotal 
role in the pathophysiology of this condition (3). However, the 
activation of the sympathetic nervous ystem in heart failure 
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does not involve heightened sympathetic nerve outflow to all 
organs in a homogeneous manner. Rather, regional sympatho- 
excitation is typically seen and appears to be preferentially 
directed to the heart and kidneys (4-6). Preferential stimula- 
tion of the cardiac sympathetic nervous outflow might have 
special relevance in that a substantial body of clinical and 
experimental evidence has identified a link between cardiac 
sympathetic nervous timulation and the genesis of ventricular 
arrhythmias (7,8). In addition, a direct toxic effect of high 
levels of norepinephrine, the sympathetic neurotransmitter, on 
the myocardium has been identified (9). 
Unexpected deaths among patients with severe heart failure 
who appear to be doing well clinically unfortunately remain a 
common occurrence. In an attempt o modify the natural 
history of heart failure by the application of more specific 
therapeutic nterventions and to establish clinical criteria for 
stratifying patients with heart failure in terms of clinical risk, 
such as might be used for establishing the relative "urgency" 
for transplantation, i vestigators have endeavored to identify 
factors that carry prognostic significance. The concentration f 
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norepinephrine in peripheral venous plasma, used as a simple, 
semiquantitative measure of overall sympathetic nervous ys- 
tem activity, has been identified as one such prognostic marker 
in patients with chronic heart failure (10). Measures of ven- 
tricular performance, including the left ventricular ejection 
fraction (11,12) and ventricular filling pressures (13), are also 
related to clinical outcome. However, these prognostic mark- 
ers tend to lose their discriminatory power in patients with 
severe heart failure, where all patients have a similar degree of 
hemodynamic compromise (14). 
Because of these circumstances, we sought o study sympa- 
thetic nervous ystem pathophysiology in human heart failure, 
with particular emphasis on cardiac sympathetic nervous activ- 
ity, and to evaluate its clinical consequences. Specifically, 
neurochemical methodology developed by us (4-6) was used 
to gauge the degree to which cardiac sympathetic nervous 
outflow was stimulated in patients with heart failure, allowing 
us to address the hypothesis that a high level of sympathetic 
activity in the heart confers a poor prognosis. Further, the 
current state of uncertainty concerning the value of beta- 
adrenergic blocking agents in the treatment of heart failure 
(15,16) provided additional incentive to examine this question. 
Methods 
General protocol. Sixty patients with moderate to severe 
heart heart failure who were entering a heart ransplantation 
waiting list were studied and followed prospectively over a 
2-year period. At enrollment, patients underwent eurochem- 
ical assessment of sympathetic nervous function, right heart 
catheterization, radionuclide measurement of left ventricular 
ejection fraction, 24-h ambulatory electrocardiographic moni- 
toring and signal-averaged lectrocardiography. S mpathetic 
nervous system testing, without he other investigations, was 
also done in 15 healthy male volunteers aged 46 + 5 years 
(mean _+ SE) who served as a reference group (6). All subjects 
read and signed a consent form for the research, which was 
approved by the Alfred Hospital Ethics Review Committee. 
Procedures. Catheterization studies. All procedures were 
performed inthe morning, and all medications were continued 
in each subject. Pulmonary artery pressure measurements 
(mean and wedge) were recorded in all patients, using a 
balloon flotation thermodilution catheter (7F Arrow, Arrow 
International). Cardiac output was measured by the thermodi- 
lution technique, and an average was calculated from three 
values, which varied by <10%. Arterial blood pressure was 
also recorded through abrachial or radial arterial catheter (3F, 
5 cm, Cook, Brisbane, Australia). After hemodynamic evalua- 
tion, a coronary sinus thermodilution catheter (Webster CCS 
7/8U 90A, Webster Laboratories) was positioned in the coro- 
nary sinus under fluoroscopic ontrol for blood sampling and 
coronary sinus blood flow measurement (17). The coronary 
sinus plasma flow was calculated after determination f each 
subject's hematocrit, for later use in computing the rate of 
norepinephrine spillover from the heart. 
Testing of sympathetic nervous function. Measurements of 
the spillover to plasma of norepinephrine from the heart and 
the body as a whole were used to estimate cardiac and overall 
sympathetic nervous activity (integrated nerve firing rate) 
(18,19). The relation that exists between the rate of sympa- 
thetic nerve firing in an organ and the overflow of norepi- 
nephrine into its venous drainage provides the experimental 
justification for the use of neurotransmitter spillover measure- 
ments in the study of sympathetic nervous function. The rate of 
release of norepinephrine from sympathetic nerve varicosities 
is unmeasurable clinically, but the norepinephrine spillover 
rate gives the rate at which released norepinephrine enters 
plasma; in humans this is -10% to 20% of the norepinephrine 
synthesis rate (18). 
The total norepinephrine spillover rate to plasma was 
measured by isotope dilution, using methods developed by us 
(18,19). Tritiated levo-norepinephrine (12 to 20 Ci/mmol) 
(New England Nuclear) was infused into an antecubital vein at 
a rate of 0.35/zCi/min per m 2 to reach steady state in plasma. 
The appearance rate of norepinephrine in plasma, with arterial 
sampling, was calculated from the following relation: 
Total norepinephrine spillover rate 
Tritiated norepinephrine fusion rate 
Plasma norepinephrine specific radioactivity" 
The infusion of tritiated norepinephrine does not signifi- 
cantly interfere with the simultaneous a say of the endogenous 
plasma norepinephrine (19). With the tracer used, the specific 
activity was sufficiently high that the plateau plasma concen- 
tration of infused norepinephrine was invariably <0.02 nmol/ 
liter, compared with endogenous plasma values >0.8 nmol/ 
liter. 
The rate of norepinephrine spillover to plasma from the 
heart was calculated according to the Fick principle, with 
acknowledgment that the flux of norepinephrine b tween the 
heart and plasma is bidirectional (4-6,18): 
Cardiac norepinephrine spillover = [(Cc~ Ca) + (Ca x ER)] X PF, 
where C~ and C~s = arterial and coronary sinus plasma 
norepinephrine concentrations, respectively; ER = fractional 
extraction of tracer norepinephrine across the heart; and PF = 
coronary sinus plasma flow. 
Left ventricular ejection fraction. Left ventricular ejection 
fraction was determined by radionuclide ventriculography in 
all patients. This method of assessing the left ventricular 
ejection fraction has previously been shown to be reproducible 
in patients with severe heart failure (20). 
Holter monitoring and signal-averaged lectrocardiography. 
Ambulatory ECG monitoring was performed in 55 patients 
(92%). The frequency and severity of ventricular ectopic 
activity, was classified according to the Lown criteria (21). 
Signal-averaged electrocardiography was performed using 
commercially available equipment (Arrhythmia Research 
Technology, model 1200 EPX). Bipolar X, Y and Z leads were 
used to record at least 250 cardiac cycles, and each lead was 
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filtered in the bidirectional mode with a corner frequency of 25 
to 250 Hz. The separate X, Y and Z filtered signals were then 
combined, and the root-mean-square was obtained. In accor- 
dance with previously established criteria, we considered late 
potentials to be present if the filtered QRS duration was 
>120 ms, the root-mean-square voltage of the terminal 40 ms 
remained below <25 ~V and the duration of the terminal 
<40/xV component persisted for at least 40 ms (22). Where a 
bundle branch block was present, the signal-averaged ECG 
study was reported as indeterminate. 
Follow-up and definitions. All patients were contacted at 
regular intervals by telephone or by direct contact in the heart 
failure clinic. Sudden death was defined as death occurring 
within 1 h of symptom onset or during sleep. Death from 
progression of heart failure was defined as death in the setting of 
inexorable hemodynamic deterioration. No patient was lost to 
follow-up. 
Biochemical assays, Arterial and coronary sinus blood 
samples were transferred immediately to ice-chilled tubes 
containing an anticoagulant ethyleneglycol-bis(beta-amino- 
ethyl ether)N,N'-tetraacetic ac d and an antioxidant (reduced 
glutathione). Plasma was then separated by centrifugation at
4°C and subsequently stored at -80°C until assay. Determina- 
tion of the plasma norepinephrine concentration was per- 
formed by high performance liquid chromatography with elec- 
trochemical detection as previously described (23). The 
integration of a fraction collector allowed the separation of 
tritiated norepinephrine and determination f its concentra- 
tion in plasma, with subsequent counting by liquid scintillation 
spectroscopy. Serum sodium and magnesium concentrations 
were determined by the Biochemistry' Department, Alfred 
Hospital. 
Statistical analysis. Group data are expressed as mean 
value _+ SE. Comparison of group mean data was performed 
by an unpaired Student t test. Survival curves were calculated 
using the Kaplan-Meier method, and patients undergoing 
transplantation were censored from further analyses at the 
time of transplantation. The significance of each variable as a 
prognostic marker was first tested in a univariate manner. The 
continuous variables, which included heart rate, mean arterial 
blood pressure, pulmonary, capillary wedge pressure, mean 
pulmona D' artery pressure, cardiac output, left ventricular 
ejection fraction, arterial plasma norcpmephrine concentra- 
tion, total body norepinephrine spillover ate, cardiac norepi- 
nephrine spillover ate, serum sodium concentration a d se- 
rum magnesium concentration, were examined by the Cox 
proportional hazards model (24). Functional (New York Heart 
Association) class, etiology of heart failure, Lown arrhythmia 
grading and presence of late potentials were classified as 
categoric variables, and their influence on survival was exam- 
ined by the log-rank test. Variables identified as significantly 
associated with outcome were then examined in a multivariate 
manner, using the Cox proportional hazards model with for- 
ward stepwise selection. All analyses were performed using 
SPSS software. The null hypothesis was rejected for p < 0.05. 
Table 1. Laboratory and Demographic Data for 60 Patients With 
Heart Failure 
NYHA class 
1I 
III 
IV 
Male/female 
LVEF (%) 
Etiology (IHD/non-IHD) 
MAP (ram Hg) 
Heart rate (beats/min) 
Cardiac output (liters/min 
Rhythm 
Sinus rhythm 
Atrial fibrillation 
Pacemaker 
PCWP (ram Hg) 
MPAP (mm Hg) 
Serum sodium (mmolfliter) 
Serum magnesium (mmol/liter) 
Arterial NE (pmol,,'liter) 
Total NE SR (pmol/min) 
Cardiac NE SR (pmol/min) 
24-h ambulatory. ECG 
Mean Lown class 
l_own class 4 
SAECG 
Late potentials 
No late potentials 
Indeterminate 
9 (15) 
47 (78) 
4 (7) 
51 (85)/9 (15) 
18.9 + 0.09 
33 (55)/27 (45) 
79.9 -+ 1.4 
83_+2 
3.8 _+ 0.l 
47 (78) 
12 (20) 
1(2) 
20.9 _+ 1.2 
28.9 -+ 1.5 
138 _+ 1 
0.84 -+ 0.01 
3,220 -+ 446 
5,419 -+ 222 
402 + 37 
3.5 -+ 0.1 
39 (65) 
11 (19) 
16 (28) 
30 (53) 
Data presented are mean value _+ SE or number (%) of patients. IHD = 
ischemic heart disease; LVEF = left ventricular ejection fraction; MAP - mean 
arterial pressure: MPAP = mean pulmonary artery pressure; NE = norepineph- 
fine; NYHA = New York Heart Association functional class; PCWP - 
pulmonary capillary- wedge pressure; SAECG = signal averaged electrocardio- 
gram; SR - spillover ate. 
Resu l ts  
Patient outcome. At the time of participation i the study, 
all patients were symptomatically and hemodynamically stable. 
All medications (angiotensin-converting e zyme inhibitors in 
97% of patients, diuretic drugs 97%, digoxin 83%, warfarin 
75% and antiarrhythmic drugs 17%) were continued because 
of concern that cessation of antifailure therapy could precipi- 
tate cardiac decompensation. I  addition to being unaccept- 
able ethically, it was thought hat the clinical applicability of 
the measures of sympathetic nervous function as potential 
prognostic indexes would be highest when tested in patients 
receiving appropriate antifailure therapy. No patient was re- 
ceiving a beta-adrenoceptor antagonist. 
The hemodynamic, neurohumoral nd electrophysiologie 
profile of the study group is detailed in Table 1. The mean 
follow-up duration was 7 -+ 1 months (range 1 to 24), during 
which time 14 patients died (7 each from sudden death and 
progressive heart failure). Nineteen patients underwent heart 
transplantation 4.5_+ 0.9 months after enrollment inthe study. 
The median survival of the study group was 17.9 months, and 
the 12-month actuarial survival rate was 75%. 
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Table 2. Group Data for Patients Who Died Versus Those Who 
Survived or Underwent Heart Transplantation 
Alive or Heart 
Transplantation Died 
(n 46) (n = 14) 
LVEF (%) 19.0 _+ 1.0 18.9 _+ 2.5 
Etiology (IHD/non-IHD) 25/21 8/6 
NYHA class 2.9 + 0.1 3.1 + 0.1 
Age (yr) 51 _+ 1 52 _+ 2 
Cardiac output (liters/min) 3.8 +- II.l 3.7 _+ 0.3 
Heart rate (beats/min) 84 _+ 2 79 _+ 4 
Rhythm 
Sinus rhythm 37 11 
Atrial fibrillation 9 3 
MAP (mm Hg) 80.8 _+ 1.7 76.9 _+ 2.3 
PCWP (mm Hg) 19.1 ± 1.3 26.7 _+ 1.3" 
MPAP (ram Hg) 26.3 + 1.7 37.3 _+ 1.8" 
Serum sodium (mmol/litcr) 138.9 + 0.5 136.3 _+ 1.4? 
Serum magnesium ( mol/liter) 0.83 + (I.ll 0.86 _+ 0.03 
Arterial NE (pmol/liter) 3,058 _+ 245 3,715 _+ 470 
Total NE SR (pmol/min) 5,358 + 486 6,156 +_ 703 
Cardiac NE SR (pmol/min) 345 + 35 592 + 87* 
24-h ambulatory ECG (% Lown class 4) 65 64 
SAECG 
Late potentials (%) 27 3 I 
No late potentials (%) 16 31 
*p < 0.01. ~p < 0.05. Data presented are mean value +_ SE or number or 
percent of patients. Abbreviations a  in Table 1. 
Predictors of mortality. Group mean data for each poten- 
tial prognostic factor are presented in Table 2 to demonstrate 
the degree of contrast between patients who died and those 
who remained alive or underwent transplantation. Univariate 
Cox analysis identified the cardiac norepinephrine spillover 
rate, mean pulmonary artery pressure, pulmonary capillary 
wedge pressure and serum sodium concentration as variables 
that were strongly associated with an adverse outcome (Table 
3), whereas mean arterial blood pressure and arterial plasma 
norepinephrine level were of borderline significance only. 
Multivariate analysis was performed by entering those vari- 
ables that were significantly associated with outcome (cardiac 
norepinephrine spillover ate, mean pulmonary artery pressure 
and serum sodium) in a Cox model. Pulmonary capillary wedge 
pressure was excluded from this analysis because of an ex- 
tremely close correlation with mean pulmonary artery pressure 
(r = 0.93). In this analysis, cardiac norepinephrine spillover 
rate was identified as the only variable significantly associated 
(p = 0.0006) with outcome. The relation between the prevail- 
ing cardiac norepinephrine spillover rate and survival is de- 
picted in Figure 1, and survival curves are compared for 
patients dichotomized by the group median because cardiac 
norepinephrine spillover rate showed a skewed distribution. 
The concentration of norepinephrine in arterial plasma in 
these patients with severe heart failure, with an identical 
method of data analysis, was found to be unrelated to subse- 
quent survival (Fig. 2). 
An evaluation of the data was also performed by excluding 
Table 3. Univariate Predictors of Mortality by Cox Proportional 
Hazards Analysis 
P 
Variable Value 
LVEF 0.73 
Etiology. 0.56 
NYHA class 0.24 
Age 0.83 
Cardiac output 0.22 
Heart rate 0.86 
Rhythm 0.84 
MAP 0.05 
PCWP <0.01 
MPAP <0.001 
Serum sodium <0.01 
Serum magnesium 0.33 
Arterial NE 0.05 
Total NE SR 0.11 
Cardiac NE SR <0.001 
24-h ambulatory ECG 0.96 
SAECG 0.68 
Abbreviations a in Table l. 
those patients undergoing transplantation, to remove any 
potential effects of patient selection bias. In this cohort, the 
median survival was 17.9 months. The Cox regression analysis 
identified the cardiac norepinephrine spillover rate (p = 
0.0003), mean pulmonary artery pressure (p = 0.002), pulmo- 
nary capillary wedge pressure (p = 0.005), serum sodium 
concentration (p = 0.002) and arterial plasma norepinephrine 
concentration (p = 0.04) as factors ignificantly associated with 
outcome. In a multivariate analysis the cardiac norepinephrine 
spillover ate was again identified as the only variable signifi- 
cantly associated with prognosis. 
Of the 14 patients who died during follow-up, 7 died of 
progressive heart failure, and 7 died suddenly, presumably of a 
ventricular arrhythmia. It was not possible to distinguish 
patients who died suddenly from those with progressive hemo- 
dynamic decompensation the basis of cardiac norepineph- 
fine kinetics or other prognostic indexes. 
Discuss ion  
Activation of the sympathetic nervous ystem is commonly 
observed in clinical and experimental heart failure. In humans, 
this activation is reflected by increased sympathetic nerve firing 
rates measured by clinical microneurography in sympathetic 
fibers passing to skeletal muscle (25), high rates of overflow of 
the sympathetic nervous transmitter norepinephrine toplasma 
(4-6) and in high plasma norepinephrine concentrations (10). 
In addition to being a characteristic feature of heart failure, 
sympathetic nervous stimulation has been ascribed a pivotal 
role in the pathophysiology of this condition (3). The notion 
that sustained sympathoexcitation may be maladaptive has 
been underlined by clinical investigations inwhich the concen- 
tration of norepinephrine in peripheral venous plasma, used as 
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Figure l. Top, Histogram depicting the frequency distribution of 
cardiac norepinephrine (NE) spillovcr ates for the patients with heart 
failure. Dashed line indicates group median (310 pmol/min); diamond 
above indicates mean cardiac norepinephrine spillover rate for healthy 
subjects, with 95% confidence limits. Cardiac norepinephrine spillover 
was significantly higher in patients with heart failure (402 + 37 vs. 
105 -+ 19, p < 0.01). Bottom, Survival curves for patients dichotomized 
by median cardiac norepinephrine spillover ate. with reduced survival 
(p = 0.01) in patients with the highest values. 
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Figure 2. Top, Histogram depicting the frequency distribution of 
norepinephrine (NE) concentration values for arterial plasma in 
patients with heart failure. Dashed line indicates the group median 
(<2,80(I pmol/liter); diamond above indicates mean norepinephrine 
plasma concentration for healthy subjects, with 95% confidence limits. 
Bottom, Survival curves for patients dichotomized by median plasma 
norepinephrine concentration, with survival not significantly different 
in patients with higher and lower values. 
a simple semiquantitative measure of overall sympathetic 
nervous system activity, has been identified as a prognostic 
marker in patients with chronic heart failure (10,26). Indirect 
support also comes from several additional clinical sources, 
from studies of beta-blockade therapy in heart failure that have 
reported beneficial effects on myocardial function (15) and 
survival (27) and from neurochemical evidence of overactivity 
of the cardiac sympathetic nerves in patients with mild cardiac 
failure with out-of-hospital ventricular tachycardia or fibrilla- 
tion (8). 
Potential cardiac effects of sympathetic overactivity. 
Mechanistically, prolonged elevation of sympathetic nervous 
activity could contribute to both the progressive decline in 
cardiac ontractile function and poor prognosis associated with 
heart failure in several ways. Increased sympathetic outflow to 
both the peripheral circulation and kidneys in cardiac failure 
may have adverse effects by causing vasoconstriction a d by 
promoting sodium retention, thereby increasing both preload 
and afterload (28). Although these peripheral manifestations 
cannot be ignored, the effects of sustained sympathetic over- 
activity in the heart are potentially far more deleterious. 
Further, the activation of the sympathetic nervous system in 
cardiac failure, in fact, preferentially involves the sympathetic 
nerves of the heart (4-6). The adverse consequences of 
prolonged elevation of adrenergic drive to the heart include 
direct toxic effects of norepinephrine on cardiac myocytes (9), 
facilitation of the development of ventricular arrhythmias 
in susceptible myocardium (7) and alterations in beta- 
adrenoceptor function (29). 
In the present study we specifically studied the sympathetic 
nerves to the heart in patients with heart failure to ascertain 
whether cardiac sympathetic overactivity is a crucial factor in 
the progressive nature of the condition and its ultimate xpres- 
sion in mortality. The concentration of norepinephrine in
peripheral venous plasma, although useful as a guide to overall 
sympathetic nervous activity (18), for several reasons does not 
provide information specific to the heart. 1) The plasma 
concentration of norepinephrine is dependent not only on its 
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rate of release from sympathetic nerves, but also on its 
clearance from plasma. In this context, the elevation in plasma 
norepinephrine typically seen in heart failure reflects both an 
increase in release and a reduction in clearance (4-6). 2) More 
important, only a few percent of the norepinephrine in plasma 
is derived from the heart (18), and therefore global measures 
of sympathetic activity, such as the venous plasma norepineph- 
rine concentration, cannot identify or quantitate cardiac sym- 
pathetic activity. In this study, the application of tracer kinetic 
techniques using radiolabeled norepinephrine avoided these 
deficiencies. 
High cardiac sympathetic activity is associated with an 
adverse outcome. Using these techniques we found that pa- 
tients with heart failure had a threefold elevation in the rate of 
norepinephrine spillover to plasma across the heart. Although 
not specifically addressed in the present study, the increased 
spillover of the neurotransmitter is predominantly attributable 
to increased rates of sympathetic nerve firing, rather than 
faulty neuronal reuptake of norepinephrine (6). In support of 
this concept, we previously showed (6) that there is also 
increased overflow from the heart of the norepinephrine 
precursor 3,4-dihydroxyphenylalanine (DOPA), the nor- 
epinephrine metabolite 3-methoxy-4-hydroxyphenylglycol 
(MHPG) and the sympathetic nervous cotransmitter neu- 
ropeptide Y in patients with heart failure. Although the rate of 
release of norepinephrine from the heart was, on average, 
higher in patients with heart failure than in healthy subjects, 
cardiac norepinephrine spillover ates differed widely, ranging 
from normal to 10 times normal. All patients had heart failure 
of sutficient degree to justify their inclusion on a heart trans- 
plantation waiting list. 
When we prospectively evaluated the prognostic value of 
cardiac norepinephrine spillover measurements compared 
with other hemodynamic, biochemical and ECG predictors of 
outcome in heart failure, the cardiac norepinephrine spillover 
rate was the only variable that was significantly associated with 
outcome in a multivariate model. In these patients with severe 
heart failure, plasma norepinephrine concentrations in periph- 
eral venous and arterial plasma were weakly related to clinical 
outcome, in contrast o the earlier reported studies, which 
included patients with more widely varying degrees of heart 
failure. A confounding effect of heart failure severity on the 
plasma concentration of norepinephrine in these studies 
(10,26) may therefore be partly responsible for the difference 
in the findings reported here. These results suggest that 
activation of the sympathetic nervous ystem, specifically of the 
cardiac sympathetic nerves, contributes to the progression of 
heart failure and sudden death. In the present study, deaths 
were equally attributable to progressive heart failure and 
sudden death, with no apparent difference in degree of cardiac 
sympathetic overactivity in either patient subset. Therefore, it
is not possible to implicate a specific effect of overactivity of 
the cardiac sympathetic nerves in contributing to a progressive 
decline in contractile performance through myocardial damage 
and beta-adrenoceptor down-regulation or alternatively facil- 
itating the development of ventricular arrhythmias. 
The present study also confirms recent descriptions (l,30) 
of the continued poor survival of patients with severe heart 
failure despite optimal medical therapy and access to heart 
transplantation. In patients with heart failure awaiting heart 
transplantation there is at present a largely unpredictable 
12-month mortality rate of -30%. Previous studies have 
identified numerous factors that are related to likelihood of 
death in heart failure in addition to measures of sympathetic 
nervous activity, such as the etiology of the heart failure (31), 
left ventricular size and filling pressures (11-13) and electro- 
physiologic measures derived from ambulatory ECG monitor- 
ing (32) and signal-averaged lectrocardiography (33). How- 
ever, the capacity of these indexes of prognosis to predict death 
or survival has been most powerful when applied to patients 
with a broad range of heart failure severity, and in the context 
of severe heart failure many lose their discriminatory capacity. 
Our findings suggest hat measurement of the cardiac norepi- 
nephrine spillover ate in patients with severe heart failure may 
provide novel prognostic information. Although right heart 
catheterization is routinely performed at transplantation cen- 
ters, the general clinical applicability of the methodology in 
determining the prognosis of patients on heart transplantation 
waiting lists is unlikely because of the specialized neuroanalytic 
radiotracer chemistry involved. 
Conclusions. The results of the present study provide the 
most direct clinical evidence to date of the deleterious effect of 
sympathetic nervous overactivity on the heart in patients with 
severe cardiac failure and emphasize that the potential value of 
protecting against his effect with agents uch as beta-blockers 
(15,16,27) and centrally acting sympathetic nervous system 
suppressants needs to be studied. 
We acknowledge the excellent contributions of Elizabeth Dewar, BSc, Leonie 
Johnston, RN and Chris Hunter. 
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